Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Croci, S.
Right arrow Articles by Lollini, P.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Croci, S.
Right arrow Articles by Lollini, P.-L.
[Cancer Research 64, 8428-8434, November 15, 2004]
© 2004 American Association for Cancer Research

Immunology

Immunological Prevention of a Multigene Cancer Syndrome

Stefania Croci1, Giordano Nicoletti1,2, Lorena Landuzzi1,2, Carla De Giovanni1,3, Annalisa Astolfi1, Chiara Marini1, Emma Di Carlo4, Piero Musiani4, Guido Forni5, Patrizia Nanni1,3 and Pier-Luigi Lollini1,3

1 Cancer Research Section, Department of Experimental Pathology and 3 Interdepartment Center for Cancer Research "Giorgio Prodi," University of Bologna, Bologna, Italy; 2 Istituti Ortopedici Rizzoli, Bologna, Italy; 4 Center of Excellence on Aging (CeSI), "G. D’Annunzio" University, Chieti, Italy; and 5 Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell–derived cytokines, in particular {gamma}-interferon, and by anti–HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The immune system effectively delays the onset and reduces the incidence of tumors, as illustrated by the enormous increase in neoplastic growth, spontaneous and carcinogen induced, observed in severely immunodepressed mice (1 , 2) . Unfortunately, the existence of tumors in mice and humans clearly shows that spontaneous immune responses are not sufficient for a complete prevention of carcinogenesis. Conversely, it has been shown that a prophylactic activation of the immune system with vaccines and cytokines could result in a significant reduction in tumorigenesis (3) .

The effectiveness of tumor immunoprevention has been clearly shown for carcinogen-induced tumors (4) and for spontaneous tumors originating in transgenic mouse models (5) . A wide array of different immunologic strategies was used to prevent carcinomas in HER-2/neu transgenic mice, including passive administration of anti–HER-2/neu antibodies (6) , modulators of the immune response like interleukin 12 (IL-12) (7 , 8) , {alpha}-galactosylceramide (9) , or bacterial CpG sequences (10) , and various HER-2/neu–specific vaccines based on whole cells (11) , DNA (12, 13, 14, 15, 16) , peptides (17) , protein (18) , or heat shock proteins (19) . An almost complete immunoprevention of mammary carcinogenesis was obtained with a cell vaccine combining different immunologic stimuli (20) .

Immunoprevention studies were performed in mice transgenic for oncogenes; however, a hallmark of human neoplastic development is the cooperation of oncogene activation with oncosuppressor gene inactivation (21) . Most events leading to the inactivation of oncosuppressor genes entail the absence of the corresponding protein, thus leaving no target antigen for the immune system. A second issue relevant to immunoprevention is the occurrence of different tumor histotypes in individuals with identical inherited genetic defects. At present, it is not known whether cell vaccines made of a given cell type may afford protection from tumors of a different histologic origin.

To address these issues, we investigated cancer immunoprevention in a multigenic cancer syndrome. Bigenic mice carrying an activated HER-2/neu transgene and one p53 null allele develop multiple tumor types that include mammary and salivary carcinomas (22) and rhabdomyosarcomas (23) . This model system resembles human Li-Fraumeni syndrome and other cancer syndromes in which multiple mesenchymal and epithelial tumors occur in different districts in the same individual. We tested the prophylactic activity of a cell vaccine named "triplex" because it contains three immunogenic signals, namely, p185 (i.e., the gene product of HER-2/neu), combined with allogeneic major histocompatibility complex class I glycoproteins and IL-12 (20) . We show here that the triplex vaccine is highly effective in preventing the onset of multiple tumor histotypes generated by the combination of p53 knockout and HER-2/neu activation through the inhibition of specific molecular events.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Mice.
Mice transgenic for a mutant rat neu oncogene driven by an MMTVLTR and knockout for the p53 oncosuppressor gene (referred to as BALB-p53neu) were obtained by crossing BALB/c HER-2/neu transgenic (BALB-neuT) male mice with BALB/c p53+/– female mice; offspring bearing the p53+/–;neu+/– genotype then were selected by PCR analysis (23) . Parental BALB/c p53+/– mice (BALB/cJ-Trp53tm1Tyj) were purchased from The Jackson Laboratory (Bar Harbor, ME). BALB/c HER-2/neu transgenic mice were bred in our animal facilities. To study the role of antibodies in tumor prevention, BALB-p53+/– male mice and BALB-NeuT male mice were independently crossed with female BALB/c µMT mice, knockout for the immunoglobulin µ chain gene (24) , a gift from Dr. Thomas Blankenstein (Max-Dellbruck Center for Molecular Medicine, Berlin, Germany). Offspring then were interbred, and mice transgenic for the HER-2/neu oncogene (neu+/–), knockout for one p53 allele (p53+/–), and lacking B220-positive B cells (µMT/µMT) were selected. The level of B220-positive B cells was monitored by flow cytometry using monoclonal antibody RA3–6B2 (PharMingen, San Diego, CA). All of the experiments with animals were in accord with institution guidelines and were approved by the institution committee for animal use and care.

Cell Lines.
TT12 cells (here referred to as Neu/H-2q cells) were derived (25) from a mammary carcinoma developed in FVB-NeuN#202 mice, transgenic for the rat neu proto-oncogene (26) . Neu/H-2q cells express high levels of p185neu and are allogeneic to BALB/c mice. TT12 cells were transfected with a polycistronic plasmid pIL12-IRES1neo expressing murine IL-12 genes, and stable transfectants (here referred to as Neu/H-2q/IL-12 cells) were obtained and cultured as described previously (27) .

Vaccination Protocol.
Starting at the 6th week of age, BALB-p53neu female and male mice received successive 4-week courses of twice-weekly intraperitoneal vaccinations with 2 x 106 mitomycin-blocked Neu/H-2q/IL-12 cells in 0.4 mL of PBS for 2 weeks, followed by 2 weeks of rest. The vaccination protocol of mice treated with Neu/H-2q cells combined with systemic IL-12 was reported previously (20) . Briefly, mice received 4-week courses of twice-weekly intraperitoneal vaccinations with 2 x 106 cells for 2 weeks, followed by 1 week of five daily intraperitoneal administrations of recombinant mouse IL-12 (50 ng in the first course, 100 ng thereafter) provided by S. Wolf (Genetics Institute, Andover, MA) in 0.2 mL of PBS supplemented with 0.01% mouse serum albumin (Sigma Aldrich, St. Louis, MO), followed by 1 week of rest. Control BALB-p53neu mice included untreated mice, mice treated with systemic IL-12, and mice treated with Neu/H-2q cells. The vaccination courses were repeated until mice were killed or were 1 year old. Tumor development was monitored weekly.

Morphologic and Immunohistochemical Analysis.
Tissue samples obtained from BALB-p53neu mice at the indicated times were processed as described previously (28) . For histologic evaluation, formalin-fixed tissue sections were stained with H&E. For immunohistochemical analyses, the following antibodies were used: anti-p185neu (C-18; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti–proliferating cell nuclear antigen (anti-PCNA; Ylem, Rome, Italy), anti-CD11b/CD18 (Mac-1; clone M1/70.5), anti-CD8 (LyT2; clone YT5 169.4), and anti-CD4 (L3T4; clone YT5.191.1.2; all from Sera-lab, Crawley Down, Sussex, United Kingdom), anti-NK (asialo GM-1; Wako Chemicals GmbH, Neuss, Germany), and anti-GR1 (granulocytes; clone RB6–8C5; American Type Culture Collection, Manassas, VA).

PCR.
DNA and RNA were extracted from salivary gland tissue samples of BALB-p53neu mice at the indicated times by snap freezing and pulverization, followed by phenol-chloroform method. The p53 status was evaluated by a multiplex PCR on genomic DNA (0.1 µg each sample), amplifying simultaneously the p53 wild-type allele and p53 knockout allele. The amplification conditions and primer sequences were derived from The Jackson Laboratory. To study gene expression, RNA (1 µg each sample) was retrotranscribed, and semiquantitative reverse transcription-PCR was performed as described previously (29) with specific primer pairs for glyceraldehyde-3-phosphate dehydrogenase, {gamma}-interferon (IFN-{gamma}), and IL-4 (all from Clontech, Palo Alto, CA), rat HER-2/neu (5'-AGG GCA ACT TGG AGC TTA CCT ACG-3' and 5'-GGG TTC TGC CTG GGG TGG A-3'), monokine induced by IFN-{gamma} (20) , and inducible protein 10 (20) .

Cell-mediated Response.
Spleen cells were collected from treated and control BALB-p53neu mice at the indicated times. Unseparated splenocytes or fractionated subsets, positively selected by paramagnetic beads conjugated with specific monoclonal antibodies (anti-CD4, anti-CD8a, anti–CD45R-B220, and anti–NK-DX5; all from Miltenyi Biotec, Bergisch Gladbach, Germany) were cultured for 6 days at 37°C in Roswell Park Memorial Institute 1640 supplemented with 10% fetal bovine serum, containing 10 units/mL recombinant mouse IL-2 (Peprotech, Rocky Hill, NJ), alone or in the presence of mitomycin C–treated Neu/H-2q cells (10:1 splenocyte/target cell ratio). Supernatants were assayed for IFN-{gamma} and IL-4 content by ELISA assay from Endogen (Woburn, MA).

Antibody Response.
Antibody production by treated and control mice against Neu/H-2q cells was determined by cytofluorometric analysis of tumor-free mice sera as reported previously (20) .


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The Cancer Syndrome of BALB-p53neu Mice.
BALB-p53neu mice derive from a cross between mice carrying one mutant HER-2/neu transgene under transcriptional control of the mouse mammary tumor virus promoter and heterozygous p53 wild-type/null mice. All of the BALB-p53neu mice develop salivary gland carcinomas in the parotids at 13 to 15 weeks of age (22 , 23) . Female mice also are prone to mammary carcinoma with a longer latency time (~19 to 20 weeks); thus, growth of salivary tumors precedes the complete development of mammary carcinogenesis. At sacrifice, ~30% of female mice are affected by both types of tumor. In male BALB-p53neu mice, pelvic rhabdomyosarcomas (23) show latency time and growth rate similar to those of salivary gland carcinomas; thus, lethality can result from either type of neoplasm.

Vaccination of BALB-p53neu Mice Prevents Tumor Development.
We previously reported an almost complete prevention of mammary carcinogenesis in HER-2/neu transgenic mice using the triplex vaccine made of allogeneic HER-2/neu transgenic mammary carcinoma cells (named Neu/H-2q) combined with recombinant IL-12 (20) . To test the efficacy of this prophylactic approach against the complex carcinogenesis of BALB-p53neu mice, we started vaccinations at 6 weeks of age, when mammary and salivary glands are affected by atypical hyperplasia and no sign of rhabdomyosarcomagenesis is detectable in the pelvis. We used two types of vaccine that differed in the source of IL-12: one made of IL-12–transduced allogeneic mammary carcinoma cells, designated as Neu/H-2q/IL-12, and the other with cells plus exogenous recombinant IL-12, designated as Neu/H-2q + IL-12.

Vaccination of female BALB-p53neu mice resulted in an impressive long-term inhibition of carcinogenesis in the salivary and mammary glands (Fig. 1A)Citation . More than 60% of vaccinated females were completely tumor free at 1 year of age, whereas all of the untreated mice developed tumors by 20 weeks of age. Vaccination of male mice resulted in a lower proportion (25% to 40%) of tumor-free individuals at 1 year of age (Fig. 1B)Citation .



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 1. Prevention of carcinogenesis in female (A) and male (B) BALB- p53neu mice. Treatment groups consisted of 7 to 14 mice. Tumor-free survival curves of mice receiving either Neu/H-2q cells + IL-12 or Neu/H-2q/IL-12 cells were significantly different from all of the other curves (*P < 0.05, **P < 0.01 by the Mantel-Haenszel test) but were not significantly different from each other.

 
Although vaccination with IL-12–transduced cells resulted in a higher proportion of tumor-free mice than the administration of cells + IL-12 in both sexes, the difference did not reach statistical significance. All of the mice receiving either IL-12 or Neu/H-2q cells succumbed to tumors with a latency time similar to that of untreated mice (Fig. 1)Citation .

To better understand the lower preventive efficacy of immunoprevention in male mice, the incidence of rhabdomyosarcomas and salivary gland carcinomas was studied independently. Fig. 2Citation shows that the proportion of vaccinated male mice free from salivary gland tumors was similar to that of vaccinated females (compare with Fig. 1ACitation ). A higher proportion of male mice succumbed to rhabdomyosarcoma, suggesting that the latter tumor was the main determinant of the preventive efficacy of the vaccine in males.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2. Inhibition of carcinogenesis in groups of 14 to 17 BALB-p53neu male mice. Vaccinated group combines mice receiving either Neu/H-2q cells plus IL-12 or Neu/H-2q/IL-12 cells. By the Mantel-Haenszel test, salivary tumor-free survival of vaccinated mice was significantly different (P < 0.01) from that of untreated mice. Rhabdomyosarcoma-free survival of vaccinated mice was significantly different (P < 0.05) from that of untreated mice. Survival curves of vaccinated, salivary tumor-free mice and rhabdomyosarcoma-free mice were not significantly different from each other.

 
Morphologic Aspects of Tumor Immunoprevention.
Histologic examination of all of the sites of tumor development showed that vaccinated, long-term survivors up to 1 year of age were completely free from preneoplastic or neoplastic lesions, thus confirming at the microscopic level the tumor preventive efficacy of the vaccine.

We performed an in-depth analysis of tumor progression in the salivary glands because salivary gland carcinoma is the most aggressive and prevalent tumor originating in BALB-p53neu mice of both sexes. Whereas submandibular and sublingual glands appeared free from evident neoplastic lesions, parotid glands from 8-week-old mice showed, bilaterally, multiple foci of atypical hyperplasia expressing p185neu antigen and PCNA and deriving from intercalated ducts and acinic cells (Fig. 3A)Citation . In some cases, in situ carcinoma already was detectable. Poorly differentiated acinic cell carcinoma or undifferentiated carcinoma, including areas of malignant mixed tumor, developed in parotid glands of all of the mice within 20 weeks of age. The carcinogenic process was accompanied by a progressive increase in proliferating (PCNA-positive) cells expressing surface p185neu (Fig. 3A)Citation . After three courses of triplex vaccination, at 17 weeks of age, both parotid glands were almost free from neoplastic and preneoplastic lesions; membrane p185neu expression was not detectable; and the expression of PCNA was comparable with that of normal glands (Fig. 3A)Citation . At this time, focal infiltrate mainly constituted of GR1+ granulocytes and asialo GM-1+ natural killer cells could be observed close to severely injured acinic or ductal cells (Fig. 3B)Citation , suggesting the occurrence of tissue-destructive immunologic events. Some CD4+ lymphocytes were present in the interstitial stroma. Moreover, contiguous lymph nodes displayed several germinative centers, indicating an ongoing humoral response (Fig. 3C)Citation .



View larger version (155K):
[in this window]
[in a new window]
  		Fig. 3. Morphologic aspects of tumor immunoprevention. A, morphologic and immunohistochemical analysis of parotid gland carcinogenesis. For morphologic analysis, sections were stained with H&E. For immunohistochemistry, sections were stained with anti-rat p185neu or anti-PCNA monoclonal antibodies; magnification, x400. B, cellular infiltrate of reactive leukocytes in the parotid gland of a vaccinated mouse; arrows, reactive leukocytes; arrowheads, dead cells; magnification, x630. C, germinal center in lymph node adjacent to parotid gland of a vaccinated mouse; magnification, x400.

 
In vaccinated BALB-p53neu mice at 1 year of age, the morphologic features of parotid glands were largely unchanged compared with vaccinated 17-week-old mice described previously, with no sign of tumor recurrence (data not shown).

Molecular Analysis of Tumor Immunoprevention.
Carcinogenesis of BALB-p53neu mice depends on the expression of HER-2/neu and on the loss of both p53 alleles, one as the result of genetic knockout and the other as a consequence of somatic events. Expression of HER-2/neu mRNA in the parotid glands increased steadily with age in untreated mice, in parallel with progression to carcinoma (Fig. 4A)Citation . In the salivary glands of vaccinated mice, HER-2/neu expression was significantly reduced compared with carcinoma and was even lower than that of preneoplastic 4- to 8-week-old mice (Fig. 4A)Citation . This indicates that the immune mechanisms elicited by vaccination effectively prevented constitutive expression of the driving oncogene and confirms the results of immunohistochemical studies shown previously.



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. HER-2/neu expression and p53 status in parotid glands/tumors of BALB-p53neu mice. DNA and RNA were extracted from preneoplastic parotid glands of untreated female mice at 4 to 8 weeks of age (4–8 wk), from parotid tumors of 20- to 22-week-old mice (Tumors), and from parotid glands of tumor-free vaccinated mice at 52 weeks of age (Triplex). A, Expression of the HER-2/neu transgene was evaluated by semiquantitative reverse transcription-PCR. Each bar represents the mean level ± SE of three to five independent samples in which HER-2/neu expression was determined by densitometric analysis of band intensity normalized by glyceraldehyde-3-phosphate dehydrogenase intensity. The results were compared by the Student’s t test. B, Status of p53 was studied by multiplex-PCR on genomic DNA. The ratio between p53 wild-type (wt) allele band intensity and p53 knockout (KO) allele band intensity is shown for each sample. Tail represents a control tissue not affected by carcinogenesis. Each point represents one mouse.

 
By allele-specific PCR, we then analyzed the status of p53 in successive stages of salivary gland carcinogenesis. In tissues not affected by carcinogenesis (e.g., tail), the wild-type to knockout allele ratio was ~1:1 (Fig. 4B)Citation , whereas in salivary carcinomas of untreated mice, we observed an almost complete disappearance of the wild-type allele (Fig. 4B)Citation . In contrast, almost all of the parotid glands of vaccinated, long-term tumor-free mice displayed a 1:1 ratio with no loss of the wild-type p53 allele (Fig. 4B)Citation . Persistence of the wild-type p53 allele indicates that vaccination prevented an additional molecular hit required for carcinogenesis.

Cell-mediated Mechanisms in Tumor Prevention.
We previously found that the inhibition of mammary carcinoma onset in HER-2/neu transgenic mice rests on T cell–derived cytokines like IFN-{gamma} and specific antibodies, whereas T cell–mediated cytotoxicity does not play a major role (20) . The study of cytotoxic T-cell activity in vaccinated BALB-p53neu mice showed only a marginal induction of lytic activity against HER-2/neu–positive carcinoma cells (data not shown).

In the salivary gland of vaccinated mice, we found a strong induction of IFN-{gamma}, the main downstream mediator of IL-12 and of tertiary chemokines with antiangiogenic activity, such as monokine induced by IFN-{gamma} and inducible protein 10 (Fig. 5A)Citation . Spleen cells from vaccinated mice also displayed strong proliferative activity (data not shown) and cytokine secretion even without in vitro restimulation (Fig. 5B)Citation . Abundant IFN-{gamma} release by splenic CD4, CD8, and natural killer cells was observed after in vitro restimulation with Neu/H-2q cells (Fig. 5B)Citation . It is interesting to note that the cytokines produced by CD4 cells included IFN-{gamma} and IL-4, thus suggesting that the vaccine elicited a broad, nonpolarized immune response.



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5. Cytokine production elicited by vaccination. A, cytokine gene expression in parotid glands. Each bar represents the mean expression level ± SE of IFN-{gamma}, inducible protein 10, monokine induced by IFN-{gamma}, and IL-4 in parotid glands of three to five tumor-free vaccinated female mice at 52 weeks of age (Triplex), in parotid glands of untreated mice at 4 to 8 weeks of age (4–8 wk), and in carcinomas (Tumors), as determined by semiquantitative reverse transcription-PCR. Densitometric reading of band intensities was normalized by glyceraldehyde-3-phosphate dehydrogenase intensity. P values were determined by the Student’s t test. B, release of IFN-{gamma} and IL-4 by unseparated spleen cells or by fractionated subsets from untreated (14 weeks old) and vaccinated mice (52 weeks old, tumor free) either unstimulated or after in vitro restimulation with Neu/H-2q cells. Each bar represents the mean ± SE of 5 to 10 mice per group.

 
Antibody Dependency of Tumor Immunoprevention.
IFN-{gamma} is thought to play an immunoregulatory role in immunoprevention, and the most important final effectors are anti-p185neu antibodies (30) . The study of the antibody response of BALB-p53neu receiving the complete vaccine or individual components showed that only the complete vaccine was able to induce a strong antibody response (Fig. 6)Citation . Analysis of early antibody responses after the first cycle of vaccination revealed a suboptimal antibody response in a minority of vaccinated mice (Fig. 6A)Citation . Mice with high antibody levels after the first cycle of vaccination developed even higher antibody levels in the course of subsequent vaccinations (Fig. 6B)Citation . We could not extensively investigate the kinetics of antibody responses in mice with low initial antibody titers because of early tumor development. Stratification of the survival of vaccinated mice shown in Fig. 1Citation by the intensity of the early antibody response showed that early responders were long survivors, whereas late responders rapidly succumbed to tumors (Fig. 6C)Citation .



View larger version (25K):
[in this window]
[in a new window]
  		Fig. 6. Role of antibodies in tumor prevention. A, antivaccine antibodies after one vaccination course. Each symbol represents the binding to Neu/H-2q cells of diluted (1:65) sera obtained after the first course of the indicated treatments (9 weeks of age) as determined by cytofluorometric analysis. The mean fluorescence intensity (MFI) of each serum was normalized by HER-2/neu expression of Neu/H-2q cells (as determined by 7.16.4 anti-Neu monoclonal antibody binding). Horizontal bars indicate the median value of each group. The dotted line was positioned above the higher point of antibody level found in mice receiving cells alone, which were not protected by vaccination (see Fig. 1ACitation ). B, increasing antibody production in mice sera against Neu/H-2q cells during the courses of triplex vaccination evaluated by cytofluorometric analysis. Mice were bled after the first, second, third, and sixth course of vaccination. The "Early responders" group includes mice with a high antibody level (relative MFI, >60) after the first course of vaccination; the "Late responders" group includes mice with a lower antibody level. C, salivary tumor-free survival of triplex-treated mice stratified by the antibody level after the first course of vaccination. D, loss of preventive efficacy in antibody-deficient BALB-p53neu–µMT mice. Groups of 5 to 10 mice received the indicated treatments.

 
This result indicates that antibody levels elicited by the first vaccination cycle, at 9 weeks of age, are predictive of long-term (1-year) survival and of freedom from tumor onset.

To formally show that antibodies are a major determinant of immunoprevention in vaccinated mice, we crossed BALB-p53neu mice with B cell–deficient µMT mice. Vaccination of antibody-deficient BALB-p53neu–µMT mice was completely ineffective (Fig. 6D)Citation . We conclude that the major protective mechanism elicited by the vaccine was a strong specific, long-term antibody response.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We have shown here that a vaccine prevents a complex cancer syndrome caused by combined alterations in oncogenes and oncosuppressor genes. Until now, immunoprevention has been investigated exclusively in oncogene-transgenic mice and not in oncosuppressor knockout mice. A combination of oncogene activation and oncosuppressor inactivation is more akin to carcinogenetic processes occurring in nature (21) and presents additional challenges because the loss of oncosuppressor gene expression is in principle invisible to the immune system.

Protection from carcinogenesis afforded by the vaccine rested mainly on the inhibition of HER-2/neu expression in target tissues. In HER-2/neu transgenic mice, expression of p185neu is an absolute requirement for the early steps of tumor progression, as shown by the regression of established tumors after HER-2/neu deinduction in mice bearing an inducible transgene (31) . We found that spontaneous loss of p185neu expression in vitro abolished the tumorigenicity of HER-2/neu transgenic mammary carcinoma cells (25) .

The block of HER-2/neu expression in vaccinated mice was sufficient to prevent the occurrence of subsequent events in tumor progression, in particular, the loss of the remaining p53 wild-type allele. Because the assessment of p53 status was performed on whole salivary glands, we could not exclude the existence of rare p53-null cells. If such cells exist, it remains to be determined whether they are tumorigenic; in a single vaccinated mouse, we found evidence of p53 allele loss in the absence of overt neoplastic growth (see Fig. 4Citation ). To address this point, it will be interesting to analyze p53 status at the clonal level during neoplastic progression and prevention.

In theory, loss of the wild-type p53 allele should be independent of the immune response elicited by the vaccine. However, cell proliferation driven by HER-2/neu enhances the probability of additional genetic damage affecting p53; thus, the immunologic inhibition of HER-2/neu expression also entails a reduced probability of p53 loss. In a hierarchy of events leading to tumor development, the abrogation of events featuring antigenic targets can bring about a complete arrest of the carcinogenic process. In the model system used here, expression of the antigenic oncogene precedes loss of p53, but in principle immunoprevention also should work if loss of a caretaker oncosuppressor gene (21) is the first event in the process, as long as suitable downstream targets of immune response (e.g., receptor tyrosine kinases) are expressed as later events (30) .

Vaccination with mammary carcinoma cells was highly effective in preventing mammary carcinoma of female BALB-p53neu mice and salivary gland carcinoma of male and female mice but was less effective against rhabdomyosarcoma of male mice. There are several possible explanations of this difference, including the histologic origin of tumors (i.e., epithelial versus mesenchymal) and the anatomic site of onset. The most plausible explanation is a reduced immune recognition of rhabdomyosarcoma cells caused by the low expression of p185neu. We have shown previously that in rhabdomyosarcoma cells of BALB-p53neu the surface level of p185neu is one to two logs lower than in carcinomas (23) . By conventional immunohistochemistry, p185neu was barely detectable in rhabdomyosarcoma (comparable with a 0+ or 1+ score), whereas it was strongly expressed in carcinomas (a 3+ score). In human breast carcinoma, it has been clearly shown that HER-2–positive 3+ cases are responsive to therapeutic treatments with anti–HER-2 monoclonal antibodies, whereas 0+ and 1+ cases are resistant (32) . It is interesting to note that human rhabdomyosarcomas frequently express a low level of HER-2 (33) , similar to the corresponding tumors of BALB-p53neu, and are resistant to anti–HER-2 immunotoxins (34) . An old lesson for cancer immunoprevention is that tumors with a low expression of target antigens can sneak through activated immune defenses that readily arrest the progression of other tumors displaying high levels of the same antigen.

The spectrum of immune responses activated by the vaccine in BALB-p53neu mice was similar to that previously obtained in HER-2/neu transgenic mice using cell- or DNA-based vaccines (15 , 20) . In all of the cases, the vaccine elicited T- and B-cell responses, the former mainly mediated by T cell–derived cytokines, whereas the induction of CTL responses was scarce. In cancer immunotherapy, CTLs are the most important defense mechanism (2 , 13 , 15) , but in immunoprevention, there is an absolute requirement for immune responses lasting for months or even years, and it is well known that chronic CTL responses are toxic for the host (13 , 35 , 36) . Thus, a difference between cancer immunoprevention and cancer immunotherapy is that immunoprevention must be based on long-lasting, neutralizing responses with a low systemic toxicity, whereas immunotherapy is better served by acute, transient CTL responses. A parallel can be drawn with viral infections that usually are cured by intense immune responses in which CTL activity predominates, whereas prevention from subsequent reinfections is mediated by neutralizing antibodies (36) .

A clear demonstration of the key role of antibodies in our system was provided by the loss of tumor prevention in vaccinated BALB-p53neu mice lacking antibody production. The various arms of the immune system are tightly interconnected, and it is virtually impossible to abrogate just one type of response; thus, B cell–deficient mice may harbor secondary defects in their T-cell responses. However, our results as a whole point to a major role of vaccine-induced anti–HER-2/neu antibodies in the prevention of mammary carcinoma. We previously have shown that vaccine-elicited antibodies against p185neu have multiple antitumor activities, as does Herceptin administered in human neoplasia (15 , 20) . Immune functions like complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity are complemented by direct activities stemming from antibody-p185neu molecular interactions at the cell surface that determine inhibition of receptor homodimerization and heterodimerization, induction of receptor recycling, and inhibition of mitogenic signal transduction (30 , 37) . An additional reason for the importance of humoral responses against tumor progression is that antibodies efficiently bind tumor cells regardless of major histocompatibility complex expression, whereas the T-cell receptor binds a peptide–major histocompatibility complex that is frequently underexpressed by tumor cells to escape immune recognition (38, 39, 40) .

The demonstration provided here for the first time that immune strategies can effectively prevent a multigene cancer syndrome, along with recent improvements that further increase the efficacy of prophylactic DNA and cell vaccines (20 , 41, 42, 43) , indicates that cancer immunoprevention has reached a convincing preclinical stage.

However, future developments will have to consider specific features of the transgenic models. The target antigen in this system is encoded by a xenogeneic transgene; thus, one may question whether it is protected by immune tolerance as human tumor antigens are. Available experimental evidence suggests that HER-2/neu transgenic mice are tolerant to rat p185 (44) , thus implying that induction of immune responses by vaccines entails a break of tolerance.

Tumors that originate as a consequence of activated HER-2/neu expression are exquisitely dependent on HER-2/neu–driven signal transduction and are uniformly inhibited by anti-p185 antibodies. In contrast, only subsets of human carcinomas overexpressing HER-2 respond to anti-p185 trastuzumab. Recent results elucidating the molecular mechanisms of trastuzumab resistance provide additional targets for the development of combination approaches (45) .


   FOOTNOTES
 
Grant support: Associazione Italiana per la Ricerca sul Cancro, Milan, Italy, the Italian Ministry of University, and the University of Bologna. S. Croci and A. Astolfi are recipients of fellowships from Fondazione Italiana per la Ricerca sul Cancro, Milan, Italy.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Pier-Luigi Lollini, Sezione di Cancerologia, Viale Filopanti 22, I-40126 Bologna, Italy. E-mail: pierluigi.lollini{at}unibo.it

Received 7/ 1/04. Revised 9/ 8/04. Accepted 9/14/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Shankaran V, Ikeda H, Bruce AT, et al IFN{gamma} and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.[CrossRef][Medline]
  2. Pardoll D Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003;21:807-39.[CrossRef][Medline]
  3. Forni G, Lollini PL, Musiani P, Colombo MP Immunoprevention of cancer: is the time ripe?. Cancer Res 2000;60:2571-5.[Abstract/Free Full Text]
  4. Noguchi Y, Jungbluth A, Richards EC, Old LJ Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996;93:11798-801.[Abstract/Free Full Text]
  5. Lollini PL, Forni G Antitumor vaccines: is it possible to prevent a tumor?. Cancer Immunol Immunother 2002;51:409-16.[CrossRef][Medline]
  6. Katsumata M, Okudaira T, Samanta A, et al Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995;1:644-8.[CrossRef][Medline]
  7. Boggio K, Nicoletti G, Di Carlo E, et al Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.[Abstract/Free Full Text]
  8. Cifaldi L, Quaglino E, Di Carlo E, et al A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 2001;61:2809-12.[Abstract/Free Full Text]
  9. Hayakawa Y, Rovero S, Forni G, Smyth MJ {alpha}-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003;100:9464-9.[Abstract/Free Full Text]
  10. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Menard S, Balsari A Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 2002;16:1749-54.[Abstract/Free Full Text]
  11. Cefai D, Morrison BW, Sckell A, et al Targeting HER-2/neu for active- specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 1999;83:393-400.[CrossRef][Medline]
  12. Amici A, Venanzi FM, Concetti A Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998;47:183-90.[CrossRef][Medline]
  13. Rovero S, Amici A, Carlo ED, et al DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.[Abstract/Free Full Text]
  14. Pupa SM, Invernizzi AM, Forti S, et al Prevention of spontaneous neu- expressing mammary tumor development in mice transgenic for rat protoneu by DNA vaccination. Gene Ther 2001;8:75-9.[CrossRef][Medline]
  15. Curcio C, Di Carlo E, Clynes R, et al Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111:1161-70.[CrossRef][Medline]
  16. Quaglino E, Rolla S, Iezzi M, et al Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004;113:709-17.[CrossRef][Medline]
  17. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000;60:3782-9.[Abstract/Free Full Text]
  18. Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999;47:337-42.[CrossRef][Medline]
  19. Manjili MH, Wang XY, Chen X, et al HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003;171:4054-61.[Abstract/Free Full Text]
  20. Nanni P, Nicoletti G, De Giovanni C, et al Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-205.[Abstract/Free Full Text]
  21. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000;100:57-70.[CrossRef][Medline]
  22. Brodie SG, Xu X, Li C, Kuo A, Leder P, Deng CX Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 2001;20:1445-54.[CrossRef][Medline]
  23. Nanni P, Nicoletti G, De Giovanni C, et al Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res 2003;63:2728-32.[Abstract/Free Full Text]
  24. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.[CrossRef][Medline]
  25. Nanni P, Pupa SM, Nicoletti G, et al p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94.[CrossRef][Medline]
  26. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-82.[Abstract/Free Full Text]
  27. De Giovanni C, Nicoletti G, Landuzzi L, et al Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004;64:4001-9.[Abstract/Free Full Text]
  28. Di Carlo E, Diodoro MG, Boggio K, et al Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 1999;79:1261-9.[Medline]
  29. De Giovanni C, Nicoletti G, Landuzzi L, et al Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-{gamma}. Gene Ther 2001;8:1698-704.[Medline]
  30. Lollini PL, Forni G Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003;24:62-6.[CrossRef][Medline]
  31. Moody SE, Sarkisian CJ, Hahn KT, et al Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002;2:451-61.[CrossRef][Medline]
  32. Ross JS, Fletcher JA, Linette GP, et al The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.[Abstract/Free Full Text]
  33. Ricci C, Landuzzi L, Rossi I, et al Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer 2000;87:29-36.[CrossRef][Medline]
  34. Ricci C, Polito L, Nanni P, et al HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J Immunother 2002;25:314-23.
  35. Sundberg EJ, Li Y, Mariuzza RA So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Curr Opin Immunol 2002;14:36-44.[CrossRef][Medline]
  36. Ada GL The immunological principles of vaccination. Lancet 1990;335:523-6.[CrossRef][Medline]
  37. Clynes RA, Towers TL, Presta LG, Ravetch JV Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.[CrossRef][Medline]
  38. Garrido F, Algarra I MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001;83:117-58.[Medline]
  39. Seliger B, Cabrera T, Garrido F, Ferrone S HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.[CrossRef][Medline]
  40. Herrmann F, Lehr HA, Drexler I, et al HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004;64:215-20.[Abstract/Free Full Text]
  41. Wei WZ, Morris GP, Kong YC Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53:73-8.[CrossRef][Medline]
  42. Quaglino E, Iezzi M, Mastini C, et al Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res 2004;64:2858-64.[Abstract/Free Full Text]
  43. Wolpoe ME, Lutz ER, Ercolini AM, et al HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161-9.[Abstract/Free Full Text]
  44. Reilly RT, Gottlieb MB, Ercolini AM, et al HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.[Abstract/Free Full Text]
  45. Nagata Y, Lan KH, Zhou X, et al PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P. L. Lollini, G. Forni, F. Cavallo, and P. Musiani
Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression.
J. Immunol., June 15, 2006; 176(12): 7695 - 7703.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Croci, S.
Right arrow Articles by Lollini, P.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Croci, S.
Right arrow Articles by Lollini, P.-L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online